SEARCH

SEARCH BY CITATION

References

  • 1
    Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period: incidence and prognosis. Acta Med Scand 1967; 182: 491501.
  • 2
    Malchow-Møller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Staehr Johansen T, et al. Causes and characteristics of 500 consecutive causes of jaundice. Scand J Gastroenterol 1981; 16: 16.
  • 3
    Whitehead MW, Hainsworth I, Kingham JGC. The causes of obvious jaundice in South West Wales: 2000. Gut 2001; 48: 409413.
  • 4
    Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 8694.
  • 5
    Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947954.
  • 6
    Wei G, Bergqvist A, Broome U, Björnsson E. Acute liver failure in Sweden: etiology and prognosis [Abstract]. Scand J Gastroenterol 2004; 39(Suppl 240): 48A.
  • 7
    Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996; 16: 343348.
  • 8
    O'Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439445.
  • 9
    Hoofnagle JH, Carithers RL Jr, Shapiro C, Nascher H. Fulminant hepatic failure: summary of a workshop. HEPATOLOGY 1995; 21: 240252.
  • 10
    Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L, et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharm Therap 1995; 58: 108117.
  • 11
    Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000; 4: 7396.
  • 12
    Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289302.
  • 13
    Senior JR. Regulatory perspectives. In: Drug-Induced Liver Disease. KaplowitzN, DeLeveLD, eds. New York: Marcel Dekker, 2003: 739754.
  • 14
    Zimmerman HJ. Drug-induced liver disease. In: SciffER, SorrellMF, MaddreyWC, eds. Sciff′s Diseases of the Liver. 8th edition. Philadelphia: Lippincott-Raven Publishers, 1999: 9731064.
  • 15
    DavidsonCS, LeevyCM, ChamberlayneEC, eds. Guidelines for Detection of Hepatotoxicity Due to Drugs and Chemicals. Fogarthy Conference, 1978. NIH publication no. 79-313. Washington, DC: US Government Printing Office, 1979.
  • 16
    Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 13231330.
  • 17
    Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990; 11: 272276.
  • 18
    Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000; 33: 10031005.
  • 19
    Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145155.
  • 20
    Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24: 483490.
  • 21
    Zimmerman HJ. Agents employed in the treatment of infectious and paracitic diseases. In: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 1st ed. New York: Appelton-Century-Crofts, 1978: 468509.
  • 22
    Zimmerman HJ. Psychotropic and anticonvulsant agents. In: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 1st ed. New York: Appelton-Century-Crofts, 1978: 395417.
  • 23
    Zimmerman HJ. Antiinflammatory and other drugs employed in the treatment of rheumatic and musculoskeletal diseases. In: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 1st ed. New York: Appelton-Century-Crofts, 1978: 418435.
  • 24
    Zimmerman HJ. Anesthetic agents. In: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 1st ed. New York: Appelton-Century-Crofts, 1978: 370394.
  • 25
    Zimmerman HJ. Drugs used in cardiovascular disease. In Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 1st ed. New York: Appelton-Century-Crofts, 1978: 510522.
  • 26
    Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. HEPATOLOGY 2002; 36: 451455.
  • 27
    Olsson R, Brunlof G, Johansson ML, Persson M. Drug-induced hepatic injury in Sweden. HEPATOLOGY 2003; 38: 531532.
  • 28
    Björnsson E, Jerlstad P, Bergquist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden [Abstract]. Gastroenterology 2004; 126(Suppl): 1185A.
  • 29
    Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154161.
  • 30
    Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995; 49: 8185.
  • 31
    Fairley CK, McNeil JJ, Desmond P, Smallwood R, Young H, Forbes A, et al. Risk factors for development of flucloxacillin associated jaundice. BMJ 1993; 306: 233235.
  • 32
    McNeil JJ, Grabsch EA, McDonald MM. Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. Med J Aust 1999; 170: 270273.
  • 33
    Ohmori S, Shiraki K, Inoue H, Yamanaka T, Deguchi M, Sakai T, et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepato-Gastroenterology 2003; 50: 15311534.
  • 34
    Gitlin N. The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis. Am J Gastroenterol 1982; 77: 24.